Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01978314 · ClinicalTrials.gov registry record · NA
FAST GFR: Pilot Study to Evaluate the Safety of the FAST GFR Test in Patients.
A NA study of Chronic Kidney Disease and Acute Kidney Injury, sponsored by FAST BioMedical.
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT01978314: Completed NA study of Chronic Kidney Disease and Acute Kidney Injury, sponsored by FAST BioMedical.
NCT01978314 is a NA study of Chronic Kidney Disease and Acute Kidney Injury that has completed, run by FAST BioMedical. The registered enrollment target is 33 participants, below the 3,206-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01978314, a NA study of Chronic Kidney Disease and Acute Kidney Injury, has completed, sponsored by FAST BioMedical.
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single site study designed to evaluate the FAST mGFR Test™ in healthy adult volunteers, patients with varying degrees of chronic kidney disease (CKD), and patients with acute kidney injury (AKI).
Primary Outcome
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product or in
Conditions Studied
Interventions
- DEVICE 75 mg / 6 mL VFI™
Study Locations (1)
Alabama
- University of Alabama Birmingham, Division of Nephrology - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2013-08 |
| Est. Completion | 2014-08 |
| Phase | NA |
What the finished NCT01978314 record still lists
NCT01978314 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 3,206-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Chronic Kidney Disease appearing as the primary indexed condition, and to 1 intervention - of which 75 mg / 6 mL VFI™ is the first listed.
NCT01978314 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT01978314 about?
NCT01978314 is a clinical study titled "FAST GFR: Pilot Study to Evaluate the Safety of the FAST GFR Test in Patients.". This is a single site study designed to evaluate the FAST mGFR Test™ in healthy adult volunteers, patients with varying degrees of chronic kidney disease (CKD), and patients with acute kidney injury (AKI).
What is the current status of trial NCT01978314?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2013-08. Estimated completion is 2014-08.
What conditions does trial NCT01978314 study?
This clinical trial studies the following conditions: Chronic Kidney Disease, Acute Kidney Injury.
What interventions are being tested in trial NCT01978314?
The interventions under investigation include: 75 mg / 6 mL VFI™ (DEVICE).
Who is sponsoring clinical trial NCT01978314?
This trial is sponsored by FAST BioMedical, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01978314 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01978314's enrollment target sits among peer trials
33 82nd of 101 higher than 19 of 101 other Chronic Kidney Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Kidney Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pivotal Study of the Velocity™ pAVF System
RECRUITING · NA
-
Intensive Patient Referral and Education Program Prior to Renal Replacement Therapy
RECRUITING · NA
-
A Stakeholder-enhanced Intervention to Improve the Decisional Partnership of Chronic Kidney Disease Dyads (IMPART)
RECRUITING · NA
-
Transforming Hemodialysis-Related Vascular Access Education
RECRUITING · NA
-
Transcutaneous Auricular Vagus Nerve Stimulation Device in CKD Population
RECRUITING · NA
-
Staged Kidney Transplantation During Combined Heart/Kidney Transplantation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia